跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
JULUCA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
JULUCA
Authorized
STANDARD
JULUCA
viiv healthcare ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ac285cd95f623de4
Company
viiv healthcare ulc
Type
Standard
Approval Details
Approval Id
ac285cd95f623de4
Drug Approval Canada Name
JULUCA
Product Name
JULUCA
Status
Marketed
Status Date
2018-06-04
Original Market Date
2018-06-04
Din
02475774
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.16
Atc Original
J05AR21 DOLUTEGRAVIR AND RILPIVIRINE
Atc Name
j 05 ar 21
Aig Number
0260230001
Company Name
viiv healthcare ulc
Company Address
1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6
Active Ingredients
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
50 MG
RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE)
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ac285cd95f623de4
Type
Standard
Back to Health Canada Approvals